< Go Back

Focus-X Therapeutics


USA, Washington, Seattle
Macro Molecule

Focus-X Therapeutics, founded in 2020, is a preclinical stage biotechnology company committed to the discovery and development of cutting-edge radiopharmaceuticals. They focus on unmet needs in cancer diagnosis and therapy by applying their theragnostic approach to solid tumors with very low five-year survival rate. They bring proprietary radioligand therapy (RLT) to precisely deliver alpha or beta emitters to breakdown cancer cell DNA. As an emerging leader of RLT, their mission is to release the true potential of such modality by leveraging our world-class peptide drug discovery platform and joining force with top radiopharmaceutical partners.